B. Riley reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note published on Monday, January 8th, MarketBeat reports. B. Riley currently has a $205.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $220.00. B. Riley also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.60) EPS, FY2017 earnings at ($5.32) EPS, Q2 2018 earnings at ($1.46) EPS, Q3 2018 earnings at ($1.14) EPS, Q4 2018 earnings at ($1.20) EPS and FY2018 earnings at ($4.90) EPS.
Several other equities research analysts have also weighed in on the company. Goldman Sachs Group raised Alnylam Pharmaceuticals from a buy rating to a conviction-buy rating in a research report on Friday, December 15th. BidaskClub lowered Alnylam Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, December 7th. Piper Jaffray Companies reissued a buy rating and set a $182.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 17th. Cowen reissued a buy rating and set a $151.00 target price on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 9th. Finally, Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the stock an equal weight rating in a research report on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $121.20.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $125.25 on Monday. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83. The stock has a market capitalization of $12,320.00, a PE ratio of -23.86 and a beta of 2.98. Alnylam Pharmaceuticals has a 52 week low of $35.98 and a 52 week high of $147.63.
In other news, SVP Laurie Keating sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $135.89, for a total value of $4,076,700.00. Following the transaction, the senior vice president now owns 41,500 shares of the company’s stock, valued at $5,639,435. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Michael Mason sold 36,745 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total value of $4,835,274.55. Following the completion of the transaction, the vice president now directly owns 6,352 shares in the company, valued at approximately $835,859.68. The disclosure for this sale can be found here. In the last three months, insiders sold 274,075 shares of company stock worth $35,356,089. Corporate insiders own 4.30% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. California Public Employees Retirement System boosted its stake in shares of Alnylam Pharmaceuticals by 14.4% in the second quarter. California Public Employees Retirement System now owns 126,700 shares of the biopharmaceutical company’s stock valued at $10,106,000 after buying an additional 15,900 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $1,060,000. Gotham Asset Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $772,000. Bradley Foster & Sargent Inc. CT boosted its stake in shares of Alnylam Pharmaceuticals by 100.1% in the third quarter. Bradley Foster & Sargent Inc. CT now owns 8,235 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 4,120 shares in the last quarter. Finally, Nexthera Capital LP purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $8,375,000. 88.39% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by B. Riley” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/01/18/alnylam-pharmaceuticals-alny-buy-rating-reiterated-at-b-riley.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.